TL;DR

The capstone, stated plainly: getting started = getting informed. The recommended path runs concepts → mechanism → risk → evidence-reading → context, and it never arrives at a dose by design. [1] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field Polito V, Liknaitzky P (2022) doi:10.1016/j.neubiorev.2022.104706 Where studies used schedules, that lives in Protocols as referenced research, not as a starting point. Self-experimentation is worth understanding as a concept and a cautionary tale — informal self-testing is so confounded that the self-blinding study exists precisely to do better. [2] Clinical trial Self-blinding citizen science to explore psychedelic microdosing Szigeti B, Kartner L, Blemings A, Rosas F, Feilding A, Nutt DJ, Carhart-Harris RL, Erritzoe D (2021) doi:10.7554/eLife.62878 An informed decision not to proceed is a complete success. [3] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research Kuypers KPC, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D (2019) doi:10.1177/0269881119857204 Respecting that outcome is the ethic of the whole cluster. [4] Peer-reviewed Psychedelics Nichols DE (2016) doi:10.1124/pr.115.011478

Education-only. Not medical, dosing, sourcing, or legal advice. This is a reading order, not a protocol.

A path to understanding, not to a first dose. The absence of any starting instruction is deliberate.

Not an instruction guide. This cluster gives no dose, protocol, schedule, sourcing, legal clearance, or medical advice — only the concepts, risks, evidence limits, and questions to understand before any decision, including the decision not to proceed.

The library is built to be read in an order that moves from understanding to evaluation — never toward action.

A research-first path through the library
StepReadWhy here
1What a microdose is and how the field is studiedConcepts before everything
2How It WorksWhat the compound does, mechanism vs result
3Safety and InteractionsRisk before evidence of benefit
4How to evaluate what you readThe tools to judge claims
5Research literature and Use CasesSpecific claims, now readable

By the time you reach claims about specific uses, you can weigh them — which is the entire purpose of the sequence. [3] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research Kuypers KPC, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D (2019) doi:10.1177/0269881119857204

Why research-first, and why no protocol

“Research-first” names the posture exactly: the starting point is understanding the evidence, not beginning a practice. That is why no starting dose or schedule appears anywhere in this cluster — a protocol would convert orientation into instruction and make this an on-ramp to use, which it deliberately is not. Where studies used particular schedules, the Protocols material describes them as referenced research: what studies did, never your starting point. The absence is the design.

Self-experimentation is a genuine research-literacy concept, but as a personal method it is deeply confounded: without blinding you cannot separate the compound from your own expectations. The self-blinding study exists precisely because informal self-testing is so unreliable. [2] Clinical trial Self-blinding citizen science to explore psychedelic microdosing Szigeti B, Kartner L, Blemings A, Rosas F, Feilding A, Nutt DJ, Carhart-Harris RL, Erritzoe D (2021) doi:10.7554/eLife.62878 Understand it as a concept and a cautionary tale — reliable answers come from controlled research, not an n-of-one.

Respecting the decision not to proceed

If you finish informed and decide against microdosing, the cluster has done its job. Getting started meant getting informed, and an informed no is a complete success, not a dead end. [4] Peer-reviewed Psychedelics Nichols DE (2016) doi:10.1124/pr.115.011478 The whole ethic here is that the goal was never to get you to start — only to get you informed, and to respect whatever you then decide.

Getting informed has stopping points

This path does not assume the reader continues toward use. At any point — if the evidence does not match expectations, if medications or psychiatric, cardiac, pregnancy, or seizure history introduce risk, if legal status is unclear, or if the uncertainty is simply unacceptable — the informed conclusion may be to stop. That is not a failure of the process; it is one of the reasons the process exists. Reading educational material cannot evaluate personal medical history, medication interactions, or legal exposure, so when those factors are present the next step is not another article but clinician review.

Key concepts
Informed, not initiated
The deliverable is understanding and a sound decision. [1] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field Polito V, Liknaitzky P (2022) doi:10.1016/j.neubiorev.2022.104706
No protocol by design
No starting dose or schedule appears, anywhere, on purpose.
Self-testing misleads
Informal self-experimentation is too confounded to trust. [2] Clinical trial Self-blinding citizen science to explore psychedelic microdosing Szigeti B, Kartner L, Blemings A, Rosas F, Feilding A, Nutt DJ, Carhart-Harris RL, Erritzoe D (2021) doi:10.7554/eLife.62878
A valid no
An informed decision not to proceed is a complete success. [3] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research Kuypers KPC, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D (2019) doi:10.1177/0269881119857204

Frequently asked questions

What is the recommended order to read through the library?

Start with what a microdose is and how the field is studied in Foundations, then how the compound works in How It Works, then the safety and interactions material, then the research-literacy articles on reading claims and setting expectations, and only then the use-case and other context clusters. The order moves from concepts to mechanism to risk to evidence-reading, so that by the time you reach claims about specific uses you can evaluate them. It deliberately never arrives at a dose.

Why call it research-first rather than just a beginner's guide?

Because research-first names the posture exactly: the starting point is understanding the evidence, not beginning a practice. A beginner’s guide implies a beginning; this is a guide to becoming informed. The phrase also captures the order of operations — read the research and learn to read it well before forming any view — which is the opposite of the marketing-first path most newcomers stumble into.

Why isn't there a protocol or starting dose anywhere in this cluster?

By design. A protocol or starting dose would turn orientation into instruction and make this an on-ramp to use, which it deliberately is not. The cluster’s job is to help you understand the topic and decide, not to walk you toward a first dose. Where studies used particular schedules, that is described in the Protocols material as referenced research — what studies did, never as your starting point. The absence is the point, not an oversight.

Isn't self-experimentation a reasonable way to find out for myself?

Self-experimentation is a real research-literacy concept, but as a personal method it is deeply confounded: without blinding you cannot separate the drug from your expectations, and the self-blinding study exists precisely because informal self-testing is so unreliable. [2] Clinical trial Self-blinding citizen science to explore psychedelic microdosing Szigeti B, Kartner L, Blemings A, Rosas F, Feilding A, Nutt DJ, Carhart-Harris RL, Erritzoe D (2021) doi:10.7554/eLife.62878 So it is worth understanding as a concept and as a cautionary tale about why personal trials mislead — not as a recommended way to settle the question. The reliable answers come from controlled research, not from an n-of-one.

If I finish all this and decide not to microdose, what was the point?

The point was the decision itself, made well. Getting started here means getting informed, and an informed decision not to proceed is a complete success, not a dead end. You will have understood the evidence, the risks, and the open questions, and reached a conclusion you can stand behind. Respecting that outcome — for yourself and for others — is the whole ethic of the cluster: the goal was never to get you to start, only to get you informed.